Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
GSK announces first participant vaccinated in phase 3 clinical trials of its 5-in-1, meningitis ABCWY vaccine candidate
The trial will evaluate safety, tolerability and immunogenicity of GSK’s MenABCWY vaccine candidate compared to Bexsero and Menveo.
-
Low adult immunization rates decline further due to pandemic
Prior to pandemic, less than half of adults received the vaccines recommended for their age group.
-
GSK presents promising phase 2a data for chronic hepatitis B treatment
Chronic hepatitis B is a major global health problem that occurs when the body’s immune system is unable to fight off the virus.
-
Vir Biotechnology and GSK start phase 2/3 study of COVID-19 antibody treatment
Phase 2/3 study will investigate the safety and efficacy of antibody treatment in preventing hospitalisation due to COVID-19.
-
Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
Over 400 participants being enrolled in Phase 1/2 study.
-
FDA approves Trelegy Ellipta as the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US
New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm
-
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
Agreements relate to vaccine candidate using Sanofi’s recombinant protein-based technology and GSK’s pandemic adjuvant.
-
FDA approves Nucala as the first and only biologic treatment for Hypereosinophilic Syndrome (HES)
Third US indication for Nucala demonstrates GSK’s commitment to finding new ways to help patients with eosinophil-driven diseases
-
ViiV Healthcare announces start of implementation science study to identify and evaluate approaches to integrating its investigational, every-two-month, injectable HIV treatment in European healthcare practices
ViiV Healthcare work with clinical staff at 18 diverse practice sites across different healthcare systems in France, Spain, Belgium, Germany
-
ViiV Healthcare announces dolutegravir plus lamivudine three-year data confirming long-term viral suppression non-inferior to a 3-drug regimen for treatment-naïve adults with HIV-1
ViiV Healthcare present their three-year results from the phase III GEMINI 1 & 2 studies at the HIV Glasgow 2020 congress
-
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
Initial Phase 3 results may be available as early as the end of 2020; complete results are anticipated in January 2021.
-
ViiV Healthcare presents long-term switch data for Dovato demonstrating non-inferior efficacy in adults with HIV-1 and zero cases of virologic failure versus continuation of a 3-drug TAF-based regimen
The TANGO 96-week data presented at HIV Glasgow 2020 also confirm Dovato’s well-established safety and tolerability profile
-
GSK presents positive clinical data on maternal and older adults RSV candidate vaccines
Phase I/II data presented at ID Week show the two FDA fast-tracked candidate vaccines trigger robust immune response and are well-tolerated
-
ViiV Healthcare announces analysis showing no antiretroviral therapy interruptions due to COVID-19 across its clinical development programme for investigational, long-acting cabotegravir and rilpivirine
ViiV Healthcare announces analysis showing no antiretroviral
-
ViiV Healthcare presents continued positive findings from first-ever implementation science study on integrating an investigational once-monthly injectable HIV treatment into US healthcare practices
These findings build on recently presented healthcare provider and clinical staff survey perspectives.
-
ViiV Healthcare presents positive new findings from two studies of its investigational, long-acting regimen of cabotegravir and rilpivirine, including five-year data showing long-term durability, efficacy, safety, and tolerability
Positive new findings from two studies of the investigational, long-acting regimen of cabotegravir and rilpivirine for treatment of HIV.
-
GSK delivers resilient performance, strong commercial execution and further strategic progress in Q3
GSK delivers resilient performance, strong commercial execution and further strategic progress in Q3
-
GSK sets new environmental goals of net zero impact on climate and net positive impact on nature by 2030
The new goals support GSK's aim to create long-term value for shareholders and meet the needs of society.
-
ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women
The study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).
-
GSK highlights progress from the BLENREP (belantamab mafodotin-blmf) development programme in multiple myeloma at ASH Annual Meeting
Studies presented will demonstrate belantamab mafodotin's potential in combination with standard therapies in earlier lines of treatment.
